Thermo Fisher Scientific Unveils Next-generation Mass Spectrometers at ASMS 2025 to Revolutionize Biopharma Applications and Omics Research

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the launch of the Thermo Scientific Orbitrap Astral Zoom mass spectrometer (MS) and the Thermo Scientific Orbitrap Excedion Pro mass spectrometer (MS) to help push the boundaries of scientific discovery. Delivering unrivaled analytical performance and speed, the instruments are designed to uncover complex biological processes that could lead to advancements in precision medicine and significant insights for complex diseases like Alzheimer’s and cancer. These Orbitrap innovations enhance Thermo Fisher’s portfolio of industry-leading solutions, delivering a connected and powerful ecosystem that enables the success of customers in proteomics, biopharmaceutical development, and scientific research.

“Continuing our strong track record of high-impact innovation, the Orbitrap Astral Zoom and Orbitrap Excedion Pro represent a significant leap forward in mass spectrometry, enabling researchers around the world to accelerate discovery and advance the pace of transformative scientific breakthroughs,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. “With one of the industry’s broadest portfolios for omics and proteomics research – from reagents and consumables to spatial imaging systems and our state-of-the-art mass spec workflows – our solutions allow researchers to quantify and validate proteins with greater precision and scale than ever before.”

Ultimate Performance in Life Sciences Research and Discovery

Expanding on the success of the award winning Thermo Scientific Orbitrap Astral mass spectrometer, the Orbitrap Astral Zoom MS delivers unparalleled performance and is engineered to drive the next wave of breakthroughs in scientific research. The instrument enables 35% faster scan speeds, 40% higher throughput, and 50% expanded multiplexing capabilities, delivering higher sensitivity and increased experimental flexibility. With enhanced analytical coverage, research scientists can now extract richer data from their samples and accelerate transformative discoveries that could shape the future of biopharma innovation.